In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nobex Corp.

Division of Biocon Ltd.

Latest From Nobex Corp.

GenVec cuts 30% of jobs over revenue uncertainties

GenVec's stock price bounced up and down $0.10 in both directions on 25 September when the Gaithersburg, Maryland-based company announced that it will eliminate 23 jobs, or 30% of its work force, but the stock ultimately remained steady, closing at $1.69 per share from $1.68 the day before.

Immune Disorders Infectious Diseases

Ex-Alnara execs raise $15m series A for new company Allena

Allena Pharmaceuticals, a new US biotech focused on developing novel non-systemic oral protein therapeutics, has raised $15 million in series A venture capital financing. Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures led the round.


Medgenics seeks further funding for biopump technology

Medgenics, the developer of the biopump delivery system for treating chronic disease, is looking to raise $15-20 million by the middle of 2009. The combination biological/device product aims to improve protein delivery for chronic diseases than existing treatments, starting with Epodure, the delivery of erythropoietin (EPO) for anaemia.

Metabolic Disorders Cardiovascular

Executive Briefing - How to license pharmaceutical assets

Licensing is not only a mainstream activity for the pharmaceutical industry but also an intensively competitive one. Big pharma companies vie for the best opportunities, pushing up the value of highly sought after products. But how are they to know what the best opportunities are? There are literally thousands of biotech and technology companies all offering 'unique, unmissable' opportunities. This means big companies have to be very selective about which products to evaluate, and this in turn means the biotech companies must ensure that their initial presentation – which may be just 10 to 15 minutes at a bio partnering meeting – is perfectly pitched to attract the audience's attention.

Metabolic Disorders Dermatology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Protein Delivery Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Biocon Ltd.
  • Senior Management
  • Vicki Morgan, Exec. Dir., Bus. Dev.
    Russell M Savre, VP, Fin. & Admin.
  • Contact Info
  • Nobex Corp.
    Phone: (919) 474-0507
    617 Davis Dr.
    Ste. 100
    P.O. Box 13940 Durham, NC 27709-3940